Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available.
The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines.
Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors' new model and analyses the implications of its implementation.
Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Dr Sam Salek, Reader in Pharmacoepidemiology, Director - WSP Centre for Socioeconomic Research; Director - Postgraduate Course in Pharmaceutical Medicine, Cardiff University, UK.
Mr Filip Mussen, Johnson & Johnson Pharmaceuticals Research and Development, Belgium.
Prof Stuart Walker, President and Founder, International Institute for Regulatory Science, UK.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Preferred Books, Rancho Cucamonga, CA, Etats-Unis
Hardcover. Etat : Fine. 1st Edition. Fine condition. Looks unread. N° de réf. du vendeur 010271
Quantité disponible : 1 disponible(s)
Vendeur : killarneybooks, Inagh, CLARE, Irlande
Hardcover. Etat : Good+. 1st Edition. Hardcover, x + 294 pages, NOT ex-library. Interior is very good: clean and bright throughout, with unmarked text, free of inscriptions and stamps, firmly bound. Gently shelfworn boards show two tiny closed edge-nicks (upper corner of the front panel), creases to the lower spine. Issued without a dust jacket. N° de réf. du vendeur 009400
Quantité disponible : 1 disponible(s)
Vendeur : Anybook.com, Lincoln, Royaume-Uni
Etat : Good. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Clean from markings In good all round condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,750grams, ISBN:9780470060858. N° de réf. du vendeur 9470157
Quantité disponible : 1 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 4402442-n
Quantité disponible : 2 disponible(s)
Vendeur : INDOO, Avenel, NJ, Etats-Unis
Etat : New. N° de réf. du vendeur 9780470060858
Quantité disponible : Plus de 20 disponibles
Vendeur : BennettBooksLtd, Los Angeles, CA, Etats-Unis
Hardcover. Etat : New. In shrink wrap. Looks like an interesting title! N° de réf. du vendeur Q-0470060859
Quantité disponible : 1 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 4402442
Quantité disponible : 2 disponible(s)
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available. The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes and leads to an overall appraisal of benefits and risks of medicines. Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors new model and analyses the implications of its implementation. Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision makingContributes important ideas to the debate on benefit-risk appraisalProvides a future framework for benefit-risk appraisal of medicines Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9780470060858
Quantité disponible : 1 disponible(s)
Vendeur : Ubiquity Trade, Miami, FL, Etats-Unis
Etat : New. Brand new! Please provide a physical shipping address. N° de réf. du vendeur 9780470060858
Quantité disponible : Plus de 20 disponibles
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. x + 294 Index 1st Edition. N° de réf. du vendeur 26777123
Quantité disponible : 1 disponible(s)